Ad hoc announcement pursuant to Art. 53 SIX Listing Rules
Evenamide has the potential to be the first add-on therapy for patients with positive symptoms of schizophrenia
Milan, Italy – May 20, 2021 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
Milan, Italy – May 4, 2021 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies
Milan, Italy – April 13, 2021 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies
Primary objective of safety of evenamide met on all safety variables for study 010 in healthy volunteers and study 008 in patients with schizophrenia
Additional safety and
Milan, Italy, March 16, 2021 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
Global study to evaluate the reduction of levodopa-induced dyskinesia (PD LID)
Milan, Italy – March 15, 2021 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5),
Final study data intended to support the initiation of Newron’s planned phase III pivotal trial program for evenamide
Milan, Italy and Morristown, NJ, USA, January 21, 2021 -
Milan, Italy, September 15, 2020 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
- All evenamide pre-clinical studies requested by FDA completed and first clinical safety study initiated; on track to initiate evenamide Phase III program in 2021
- In advanced
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
